NECTIN4

Chr 1AR

nectin cell adhesion molecule 4

Also known as: EDSS1, LNIR, PRR4, PVRL4, nectin-4

This gene encodes a member of the nectin family. The encoded protein contains two immunoglobulin-like (Ig-like) C2-type domains and one Ig-like V-type domain. It is involved in cell adhesion through trans-homophilic and -heterophilic interactions. It is a single-pass type I membrane protein. The soluble form is produced by proteolytic cleavage at the cell surface by the metalloproteinase ADAM17/TACE. The secreted form is found in both breast tumor cell lines and breast tumor patients. Mutations in this gene are the cause of ectodermal dysplasia-syndactyly syndrome type 1, an autosomal recessive disorder. Alternatively spliced transcript variants have been found but the full-length nature of the variant has not been determined.[provided by RefSeq, Jan 2011]

OMIMResearchGenerating clinical summary…
LOFmechanismARLOEUF 0.391 OMIM phenotype
Clinical SummaryNECTIN4
Population Constraint (gnomAD)
Moderately constrained gene (pLI 0.84) — some intolerance to loss-of-function variants.
📋
ClinVar Variants
12 unique Pathogenic / Likely Pathogenic· 23 VUS of 93 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?
0.39LOEUF
pLI 0.835
Z-score 3.73
OE 0.17 (0.080.39)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
1.28Z-score
OE missense 0.80 (0.720.88)
248 obs / 311.5 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.17 (0.080.39)
00.351.4
Missense OE?0.80 (0.720.88)
00.61.4
Synonymous OE?0.99
01.21.6
LoF obs/exp: 4 / 23.5Missense obs/exp: 248 / 311.5Syn Z: 0.14
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveNECTIN4-related ectodermal dysplasia-syndactyly syndromeLOFAR

This gene — mechanism propensity

Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.

DN
0.6550th %ile
GOF
0.72top 25%
LOF
0.3552th %ile

The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

93 submitted variants in ClinVar

Classification Summary

Pathogenic10
Likely Pathogenic2
VUS23
Likely Benign34
Benign12
Conflicting1
10
Pathogenic
2
Likely Pathogenic
23
VUS
34
Likely Benign
12
Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
6
4
0
0
10
Likely Pathogenic
1
1
0
0
2
VUS
0
22
0
1
23
Likely Benign
0
1
5
28
34
Benign
0
4
2
6
12
Conflicting
1
Total73273582

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

12 pathogenic / likely-pathogenic (of 20) ClinVar copy-number / structural variants overlap NECTIN4 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

NECTIN4 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

TNBC - Triple-Negative Breast CancerHR+ Breast Cancer

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

NOT YET RECRUITING
NCT07080619Phase PHASE2Tianjin ConjuStar Biologics Co., Ltd.Started 2025-09-20
SC-101
Metastatic Penile Squamous Cell CarcinomaStage III Penile Cancer AJCC v8Stage IV Penile Cancer AJCC v8

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

RECRUITING
NCT06104618Phase PHASE2Mayo ClinicStarted 2023-12-21
Enfortumab VedotinComputed TomographyMagnetic Resonance Imaging
Triple-negative Breast Cancer

JS207 Combination Therapy in Triple-negative Breast Cancer

RECRUITING
NCT07045311Phase PHASE2Shanghai Junshi Bioscience Co., Ltd.Started 2025-09-17
JS207 in combination with 9MW2821JS207 in combination with Albumin paclitaxel
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

ACTIVE NOT RECRUITING
NCT06238479Phase PHASE1Eli Lilly and CompanyStarted 2024-03-05
LY4101174
Advanced Non Small Cell Lung Cancer (NSCLC)

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

NOT YET RECRUITING
NCT07669779Phase PHASE2AkesoStarted 2026-06-30
AK146D1 for injectionAK112 InjectionPlatinum chemotherapy
Advanced Hepatocellular Carcinoma (HCC)

A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma

RECRUITING
NCT06902389Phase PHASE1, PHASE2Eastern Hepatobiliary Surgery HospitalStarted 2025-07-30
Super Hi-TCR-T cells
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableUpper Tract Urothelial Cancer

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

RECRUITING
NCT06820255Phase PHASE4Fondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-01-07
Platinum + GemcitabineAvelumab first-line maintenanceNGS test for DDR alterations
Advanced Urothelial Carcinoma

A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma

ACTIVE NOT RECRUITING
NCT07063758National Taiwan University Clinical Trial CenterStarted 2025-04-01
Biomarker Analysis
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

RECRUITING
NCT06823427Phase PHASE2Mabwell (Shanghai) Bioscience Co., Ltd.Started 2025-01-17
9MW2821Toripalimab (JS001 )
Muscle-Invasive Bladder CarcinomaMetastatic Urothelial Carcinoma

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

RECRUITING
NCT06493552Phase PHASE2, PHASE3Vasgene Therapeutics, IncStarted 2025-03-15
SEphB4-HSAPembrolizumabGemcitabine
Infiltrating Bladder Urothelial Carcinoma With Squamous DifferentiationLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

RECRUITING
NCT04878029Phase PHASE1Emory UniversityStarted 2021-07-23
Cabozantinib S-malateEnfortumab VedotinQuality-of-Life Assessment
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

ENROLLING BY INVITATION
NCT07218003Phase PHASE1Rondo TherapeuticsStarted 2025-11-17
RNDO-564Pembrolizumab